Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 35 clinical trials
NUVOLA TRIAL Open-label Multicentre Study

peritoneal tumour load. Nonetheless, BRCAmut women additionally show a higher benefit of platinum-based neoadjuvant chemotherapy (NACT) plus interval debulking surgery compared with BRCAwt women in

  • 0 views
  • 23 Jan, 2021
  • 1 location
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.

tumor debulking
paclitaxel
carboplatin/paclitaxel
serous cystadenocarcinoma
epithelial ovarian cancer
  • 26 views
  • 20 Sep, 2021
  • 95 locations
Comparative Effectiveness of HIPEC Following Interval Debulking Surgery in Patients With Advanced-stage Ovarian Cancer

status. Neoadjuvant chemotherapy(NAC) followed interval debulking surgery (IDS) is an alternative therapeutic option for these patients. There is growing interest in the use of HIPEC (hyperthermic

ovarian epithelial carcinoma
cytoreductive surgery
cancer chemotherapy
tumor debulking
interval debulking surgery
  • 8 views
  • 23 Jan, 2021
  • 1 location
Prehabilitation in Patients With Advanced Stage Ovarian Cancer Planned for Interval Debulking Surgery

There is a strong evidence of positive effect of multimodal prehabilitation from prospective controlled trials among patients treated surgically for non-gynaecological cancer. However, the number of studies published on prehabilitation programs in gynaecologic surgery are limited, especially in gynaecologic cancer patients. No study or trial comprehensively evaluating a prehabilitation pathway …

  • 0 views
  • 16 Mar, 2021
  • 1 location
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)

This is a phase III, multicenter, interventional and randomized study which evaluates the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) coupled with either Primary Debulking Surgery

tumor debulking
ovarian carcinoma
liver metastasis
mucinous adenocarcinoma
cytoreduction
  • 3 views
  • 22 Jan, 2021
  • 12 locations
Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian Fallopian and Primary Peritoneal Cancer

Te hypothesized that two cycles of neoadjuvant chemotherapy followed by interval debulking surgery would improve survival in advanced epithelial ovarian, fallopian, and primary peritoneal cancer

cytoreductive surgery
neutrophil count
cancer chemotherapy
tumor debulking
cancer antigen 125
  • 45 views
  • 23 Jan, 2021
Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting

This study aims to evaluate the effects of niraparib in those who have received neoadjuvant chemotherapy and subsequent interval debulking surgery, with or without hyperthermic intraperitoneal

cytoreductive surgery
tumor debulking
cancer chemotherapy
interval debulking surgery
cancer of the ovary
  • 0 views
  • 25 Jan, 2021
  • 1 location
Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

This study tests the hypothesis that IV iron sucrose infusions given to iron deficient ovarian cancer patients prior to debulking surgery can improve pre-operative iron stores and decrease

iron
transferrin saturation
debulking surgery
blood transfusion
venofer
  • 1 views
  • 27 Jan, 2021
  • 1 location
Paclitaxel i.v. Plus Cisplatin i.p for NACT in Patients With Advanced Ovarian Cancer

arm clinical trial. Included patients will receive interval debulking surgery after 2-6 cycles neoadjuvant chemotherapy based on the clinical judgment of the gynecologic oncologist. Six cycles of

  • 0 views
  • 18 Aug, 2021
  • 1 location
Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy

surgery. [18F]FB-IL2 PET-CT will be used for the non-invasive assessment of T-cell activation and correlated to immunohistochemistry tumor tissue data from pre-treatment biopsy and interval debulking

tumor debulking
cancer chemotherapy
interval debulking surgery
cancer of the ovary
ascites
  • 2 views
  • 23 May, 2021
  • 1 location